Roche buys neuromuscular play Trophos

Roche (SIX:ROG; OTCQX:RHHBY) acquired neuromuscular disease play Trophos S.A. (Marseille, France) for EUR 120 million ($141.8 million) in upfront cash. Trophos shareholders are eligible for up to EUR 350 million ($413.6 million) in milestones.

Last year, Trophos' olesoxime ( TRO19622) met the primary endpoint of preventing loss of motor function in a Phase II/III trial to treat spinal muscular atrophy (SMA) (see BioCentury Extra, March 10, 2014). ...